Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data

被引:135
作者
Nicolaides, E
Galia, E
Efthymiopoulos, C
Dressman, JB
Reppas, C [1 ]
机构
[1] Univ Athens, Dept Pharm, Athens, Greece
[2] Univ Frankfurt, Inst Pharmazeut Technol, Frankfurt, Germany
[3] GlaxoWellcome R&D, Greenford, Middx, England
关键词
dissolution; low solubility drugs; troglitazone; atovaquone; sanfetrinem cilexetil;
D O I
10.1023/A:1018959511323
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To assess the usefulness of biorelevant dissolution tests in predicting food and formulation effects on the absorption of four poorly soluble, lipophilic drugs. Methods. Dissolution was studied with USP Apparatus II in water, milk, SIFsp, FaSSIF, and FeSSIF. The in vitro dissolution data were compared on a rank order basis with existing in civet data for the tested products under fasted and fed state conditions. Results. All drugs/formulations showed more complete dissolution in bile salt/lecithin containing media and in milk than in water and SIFsp, (USP 23). Comparisons of the in vitro dissolution data in biorelevant media with in vivo data showed that in all cases it was possible to forecast food effects and differences in absorption between products of the same drug with the physiologically relevant media (FaSSIF, FeSSIF and milk). Differences between products (both in vitro or in vivo) were less pronounced than differences due to media composition (in vitro) or dosing conditions (in vivo). Conclusions. Although biorelevant dissolution tests still have issues which will require further refinement, they offer a promising in vitro tool for forecasting the in vivo performance of poorly soluble drugs.
引用
收藏
页码:1876 / 1882
页数:7
相关论文
共 20 条
[1]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[2]   Regulation of gastric and pancreatic lipase secretion by CCK and cholinergic mechanisms in humans [J].
Borovicka, J ;
Schwizer, W ;
Mettraux, C ;
Kreiss, C ;
Remy, B ;
Asal, K ;
Jansen, JBMJ ;
Douchet, I ;
Verger, R ;
Fried, M .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1997, 273 (02) :G374-G380
[3]   Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms [J].
Dressman, JB ;
Amidon, GL ;
Reppas, C ;
Shah, VP .
PHARMACEUTICAL RESEARCH, 1998, 15 (01) :11-22
[4]  
Florence A.T., 1988, PHYSICOCHEMICAL PRIN, V2nd ed.
[5]   IONIC CONSTITUENTS AND OSMOLALITY OF GASTRIC AND SMALL-INTESTINAL FLUIDS AFTER EATING [J].
FORDTRAN, JS ;
LOCKLEAR, TW .
AMERICAN JOURNAL OF DIGESTIVE DISEASES, 1966, 11 (07) :503-&
[6]   Photooxidation of troglitazone, a new antidiabetic drug [J].
Fu, YL ;
Sheu, CM ;
Fujita, T ;
Foote, CS .
PHOTOCHEMISTRY AND PHOTOBIOLOGY, 1996, 63 (05) :615-620
[7]   Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs [J].
Galia, E ;
Nicolaides, E ;
Hörter, D ;
Löbenberg, R ;
Reppas, C ;
Dressman, JB .
PHARMACEUTICAL RESEARCH, 1998, 15 (05) :698-705
[8]  
GALIA E, 1998, PHARMSCI S, V1, pS491
[9]   Sanfetrinem and sanfetrinem-cilexetil: Disposition in rat and dog [J].
Iavarone, L ;
Bottacini, M ;
Pugnaghi, F ;
Morandini, C ;
Grossi, P .
XENOBIOTICA, 1997, 27 (07) :693-709
[10]   Troglitazone: Review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus [J].
Johnson, MD ;
Campbell, LK ;
Campbell, RK .
ANNALS OF PHARMACOTHERAPY, 1998, 32 (03) :337-348